Bianca Pollo

List of Publications by Year
in descending order

204 papers	36,160 citations	13865 67 h-index	4117 175 g-index
211 all docs	211 docs citations	211 times ranked	45700 citing authors

#	Article	IF	Citations
1	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	28.9	3,979
2	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	14.3	3,706
3	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	27.0	2,582
4	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	28.9	2,277
5	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	28.9	2,111
6	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	28.9	1,718
7	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	28.9	1,670
8	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, 2018, 173, 338-354.e15.	28.9	1,417
9	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	6.4	801
10	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	16.8	750
11	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Reports, 2018, 23, 181-193.e7.	6.4	683
12	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 2018, 34, 211-224.e6.	16.8	623
13	Pathogenic Germline Variants in 10,389 Adult Cancers. Cell, 2018, 173, 355-370.e14.	28.9	620
14	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems, 2018, 6, 271-281.e7.	6.2	605
15	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	6.4	523
16	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	16.8	478
17	Gene therapy of experimental brain tumors using neural progenitor cells. Nature Medicine, 2000, 6, 447-450.	30.7	450
18	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Reports, 2018, 23, 227-238.e3.	6.4	407

#	ARTICLE	IF	CITATIONS
19	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell, 2018, 33, 706-720.e9.	16.8	400
20	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	16.8	396
21	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports, 2018, 23, 282-296.e4.	6.4	333
22	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Reports, 2018, 25, 1304-1317.e5.	6.4	329
23	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 2018, 6, 282-300.e2.	6.2	284
24	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10.	28.9	272
25	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
26	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell, 2018, 173, 386-399.e12.	28.9	228
27	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports, 2018, 23, 297-312.e12.	6.4	205
28	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Reports, 2018, 23, 255-269.e4.	6.4	204
29	Expression of Drug Resistance Proteins Pgp, MRP1, MRP3, MRP5 AND GST-π in Human Glioma. Journal of Neuro-Oncology, 2005, 74, 113-121.	2.9	187
30	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	1.2	184
31	Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene, 2009, 28, 1807-1811.	5.9	177
32	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Reports, 2018, 23, 270-281.e3.	6.4	177
33	Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro-Oncology, 2008, 10, 79-87.	1.2	172
34	Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO). Clinical Cancer Research, 2018, 24, 52-61.	7.0	162
35	Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival. Clinical Cancer Research, 2007, 13, 2606-2613.	7.0	144
36	Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma. Journal of Clinical Oncology, 2009, 27, 566-571.	1.6	140

#	Article	IF	Citations
37	Histologic prognostic factors in ependymoma. Child's Nervous System, 1991, 7, 177-82.	1.1	138
38	The "Bystander Effect" Association of U-87 Cell Death with Ganciclovir-Mediated Apoptosis of Nearby Cells and Lack of Effect in Athymic Mice. Human Gene Therapy, 1995, 6, 763-772.	2.7	135
39	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Systems, 2018, 7, 422-437.e7.	6.2	134
40	Is fluorescein-guided technique able to help in resection of high-grade gliomas?. Neurosurgical Focus, 2014, 36, E5.	2.3	133
41	hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. British Journal of Cancer, 2005, 93, 781-792.	6.4	129
42	Fluorescein-guided surgery for grade IV gliomas with a dedicated filter on the surgical microscope: preliminary results in 12 cases. Acta Neurochirurgica, 2013, 155, 1277-1286.	1.7	124
43	The *MET* Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype. Cancer Research, 2012, 72, 4537-4550.	0.9	120
44	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports, 2018, 23, 172-180.e3.	6.4	119
45	Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro-Oncology, 2016, 18, 1451-1460.	1.2	108
46	Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Archiv A, Pathological Anatomy and Histopathology, 1991, 419, 417-423.	1.4	102
47	Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology, 2019, 21, i18-i31.	1.2	102
48	B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine, 2019, 47, 33-43.	6.1	101
49	L-2-hydroxyglutaric aciduria and brain malignant tumors. Neurology, 2004, 62, 1882-1884.	1.1	100
50	Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathologica Communications, 2015, 3, 4.	5.2	100
51	Imaging and diagnostic advances for intracranial meningiomas. Neuro-Oncology, 2019, 21, i44-i61.	1.2	100
52	Identification of residual tumor with intraoperative contrast-enhanced ultrasound during glioblastoma resection. Neurosurgical Focus, 2016, 40, E7.	2.3	99
53	Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene, 2006, 25, 1571-1583.	5.9	96
54	Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Science Translational Medicine, 2018, 10, .	12.4	96

#	Article	IF	Citations
55	Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1336-1345.	0.8	93
56	Molecular and translational advances in meningiomas. Neuro-Oncology, 2019, 21, i4-i17.	1.2	92
57	Cerebral preamyloid deposits and congophilic angiopathy in aged dogs. Neuroscience Letters, 1990, 114, 178-183.	2.1	89
58	Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. Journal of Experimental and Clinical Cancer Research, 2016, 35, 55.	8.6	89
59	Free cytoplasmic Ca^{++} at rest and after cholinergic stimulus is increased in cultured muscle cells from Duchenne muscular dystrophy patients. Neurology, 1988, 38, 476-476.	1.1	87
60	ï»¿CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biology and Therapy, 2009, 8, 1608-1614.	3.4	83
61	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Reports, 2018, 23, 213-226.e3.	6.4	83
62	Epilepsy in cerebral glioma: timing of appearance and histological correlations. Journal of Neuro-Oncology, 2009, 93, 395-400.	2.9	78
63	The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines. Oncogene, 2003, 22, 2581-2591.	5.9	76
64	CXCL12 in Malignant Glial Tumors: A Possible Role in Angiogenesis and Cross-Talk between Endothelial and Tumoral Cells. Journal of Neuro-Oncology, 2004, 67, 305-317.	2.9	72
65	Limited Efficacy of the HSV-TK/GCV System for Gene Therapy of Malignant Gliomas and Perspectives for the Combined Transduction of the Interleukin-4 Gene. Human Gene Therapy, 1997, 8, 1345-1353.	2.7	69
66	Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro-Oncology, 2014, 16, 719-727.	1.2	68
67	Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Molecular Cancer, 2004, 3, 25.	19.2	66
68	New Insights Into Brain Damage in Stroke-Prone Rats. Stroke, 2002, 33, 825-830.	2.0	61
69	Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. Journal of Neuro-Oncology, 2009, 93, 319-324.	2.9	61
70	Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. Journal of Neuro-Oncology, 2014, 118, 305-312.	2.9	61
71	The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. OncoImmunology, 2013, 2, e23401.	4.6	56
72	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. Neuro-Oncology, 2019, 21, i32-i43.	1.2	56

#	Article	IF	Citations
73	Alzheimer patients and Down patients: Abnormal presynaptic terminals are related to cerebral preamyloid deposits. Neuroscience Letters, 1990, 119, 56-59.	2.1	55
74	Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. International Journal of Cancer, 2003, 107, 493-497.	5.1	55
75	Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology. American Journal of Surgical Pathology, 2019, 43, 56-63.	3.7	55
76	Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8^{+} T cell activation in the presence of adjuvant temozolomide. OncoImmunology, 2018, 7, e1412901.	4.6	54
77	CXCL12 Expression is Predictive of a Shorter Time to Tumor Progression in Low-Grade Glioma: A Single-Institution Study in 50 Patients. Journal of Neuro-Oncology, 2005, 74, 287-293.	2.9	53
78	Increasing complexity of the karyotype in 50 human gliomas. Cancer Genetics and Cytogenetics, 1994, 75, 77-89.	1.0	51
79	Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. Neuroscience Letters, 2004, 370, 180-185.	2.1	51
80	Reclassification of oligoastrocytomas by loss of heterozygosity studies. International Journal of Cancer, 2006, 119, 84-90.	5.1	51
81	Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. European Journal of Nuclear Medicine and Molecular Imaging, 1994, 21, 314-321.	2.1	50
82	ÃŸPP Participates in PrP-Amyloid Plaques of Gerstmann-StrÃ¤ussler-Scheinker Disease, Indiana Kindred. Journal of Neuropathology and Experimental Neurology, 1993, 52, 64-70.	1.7	49
83	Nestin, PDGFR-Î², CXCL12 and VEGF in gliomapatients: Different profiles of (Pro-Angiogenic) molecule expression are related with tumor grade and may provide prognostic information. Cancer Biology and Therapy, 2007, 6, 1018-1024.	3.4	49
84	Aquaporin-4 contributes to the resolution of peritumoural brain oedema in human glioblastoma multiforme after combined chemotherapy and radiotherapy. European Journal of Cancer, 2009, 45, 3315-3325.	2.8	48
85	Loss of H3K27me3 in meningiomas. Neuro-Oncology, 2021, 23, 1282-1291.	1.2	45
86	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. Acta Neuropathologica, 2019, 137, 837-846.	7.7	43
87	Expression of the new CXCL12 receptor, CXCR7, in gliomas. Cancer Biology and Therapy, 2011, 11, 242-253.	3.4	41
88	Histological variants of medulloblastoma are the most powerful clinical prognostic indicators. Pediatric Blood and Cancer, 2013, 60, 210-216.	1.5	38
89	Dexamethasone inhibits the anti-tumor effect of interleukin 4 on rat experimental gliomas. Gene Therapy, 2003, 10, 188-192.	4.5	36
90	Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurological Sciences, 2007, 28, 304-310.	1.9	36

#	ARTICLE	IF	CITATIONS
91	Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biology and Therapy, 2006, 5, 827-832.	3.4	35
92	Microglia immunophenotyping in gliomas. Oncology Letters, 2018, 15, 998-1006.	1.8	35
93	Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro-Oncology, 2016, 126, 279-288.	2.9	33
94	Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Annals of Neurology, 2002, 52, 842-845.	5.3	32
95	Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. Neuro-Oncology, 2007, 9, 298-307.	1.2	31
96	Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. Nucleic Acids Research, 2018, 46, 3817-3832.	14.5	31
97	Multidrug resistance proteins expression in glioma patients with epilepsy. Journal of Neuro-Oncology, 2012, 110, 129-135.	2.9	30
98	First ex vivo validation of a radioguided surgery technique withβ-radiation.. Physica Medica, 2016, 32, 1139-1144.	0.7	30
99	An Optimized Method for Manufacturing a Clinical Scale Dendritic Cell-Based Vaccine for the Treatment of Glioblastoma. PLoS ONE, 2012, 7, e52301.	2.5	30
100	MUCINOUS LOW-GRADE ADENOCARCINOMA ARISING IN AN INTRACRANIAL ENTEROGENOUS CYST. Neurosurgery, 2008, 62, E972-E973.	1.1	27
101	Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. Journal of Neurosurgery, 2013, 118, 821-829.	1.6	26
102	Microfragmented human fat tissue is a natural scaffold for drug delivery: Potential application in cancer chemotherapy. Journal of Controlled Release, 2019, 302, 2-18.	9.9	26
103	Ex Vivo Fluorescein-Assisted Confocal Laser Endomicroscopy (CONVIVOÂ® System) in Patients With Glioblastoma: Results From a Prospective Study. Frontiers in Oncology, 2020, 10, 606574.	2.8	26
104	FABP4 is a candidate marker of cerebellar liponeurocytomas. Journal of Neuro-Oncology, 2012, 108, 513-519.	2.9	25
105	Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. Neuro-Oncology, 2021, 23, 848-857.	1.2	24
106	High frequency of the H63D mutation of the hemochromatosis gene (HFE) in malignant gliomas. Neurology, 2001, 57, 1342-1342.	1.1	23
107	Anaplasia Is Rare and Does Not Influence Prognosis in Adult Medulloblastoma. Journal of Neuropathology and Experimental Neurology, 2005, 64, 869-874.	1.7	22
108	A Case of Pediatric Tumefactive Demyelinating Lesion Misdiagnosed and Treated as Glioblastoma. Journal of Child Neurology, 2008, 23, 944-947.	1.4	22

#	Article	IF	Citations
109	DNA Microarray Analysis Identifies *CKS2* and *LEPR* as Potential Markers of Meningioma Recurrence. Oncologist, 2011, 16, 1440-1450.	3.7	22
110	Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. Journal of Clinical Oncology, 2015, 33, 1943-1950.	1.6	21
111	Altered function of the glutamate–aspartate transporter GLAST, a potential therapeutic target in glioblastoma. International Journal of Cancer, 2019, 144, 2539-2554.	5.1	21
112	Radiation-induced glioblastoma in a medulloblastoma patient: A case report with molecular features. Neuropathology, 2008, 28, 633-639.	1.2	20
113	Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma. Journal of Neuro-Oncology, 2012, 108, 163-171.	2.9	20
114	Adult medulloblastoma: multiagent chemotherapy with cisplatinum and etoposide: a single institutional experience. Journal of Neuro-Oncology, 2012, 106, 595-600.	2.9	20
115	Primary central nervous system angiosarcoma: A case report and literature review. Neuropathology, 2015, 35, 184-191.	1.2	20
116	High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. Cancer Immunology, Immunotherapy, 2021, 70, 831-842.	4.2	20
117	Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. Journal of Neuro-Oncology, 2003, 64, 193-201.	2.9	19
118	Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience. Journal of Neuro-Oncology, 2007, 82, 273-279.	2.9	19
119	Growth hormone and prolactin responses to corticotrophin-releasing-hormone in patients with Cushing's disease: a paracrine action of the adenomatous corticotrophic cells?. Clinical Endocrinology, 1998, 49, 433-439.	2.4	18
120	Neuropathological diagnosis of brain tumours. Neurological Sciences, 2011, 32, 209-211.	1.9	18
121	ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. Cell Reports, 2021, 36, 109455.	6.4	18
122	LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response. Science Translational Medicine, 2021, 13, eabf7036.	12.4	18
123	Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim–Chester disease. Journal of Neurology, 2018, 265, 273-284.	3.6	17
124	Gliomatosis cerebri. Report of a case with isolated amnesic disorders. Italian Journal of Neurological Sciences, 1992, 13, 503-506.	0.1	16
125	Loss of heterozygosity studies in extracranial metastatic meningiomas. Journal of Neuro-Oncology, 2007, 85, 81-85.	2.9	16
126	Late-onset sporadic ataxia, pontine lesion, and retroperitoneal fibrosis: a case of Erdheim-Chester disease. Neurological Sciences, 2008, 29, 263-267.	1.9	16

#	Article	IF	Citations
127	Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. Neuro-Oncology Advances, 2019, 1, vdz022.	0.7	16
128	Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas. American Journal of Surgical Pathology, 2021, 45, 200-204.	3.7	16
129	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. Journal of Neurosurgical Sciences, 2020, 64, 313-334.	0.6	15
130	Meningitis following relapsing painful ophthalmoplegia in aspergillus sphenoidal sinusitis: a case report. Neurological Sciences, 2006, 27, 284-287.	1.9	14
131	Expression profile of frizzled receptors in human medulloblastomas. Journal of Neuro-Oncology, 2012, 106, 271-280.	2.9	14
132	Case report: long-term survival of an infant syndromic patient affected by atypical teratoid-rhabdoid tumor. BMC Cancer, 2013, 13, 100.	2.6	14
133	Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. Molecular Cancer, 2013, 12, 160.	19.2	14
134	Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood. Journal of Neuro-Oncology, 2019, 142, 435-444.	2.9	14
135	Intravascular lymphomatosis (IL) in a child mimicking a posterior fossa tumor. Journal of Neuro-Oncology, 2001, 51, 47-50.	2.9	13
136	Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience. Neurological Sciences, 2013, 34, 2151-2157.	1.9	13
137	The <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi>Î²</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml: radio-guided surgery: Method to estimate the minimum injectable activity from ex-vivo test. Physica Medica, 2019, 58, 114-120.	0.7	13
138	In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. Neurological Sciences, 2020, 41, 347-355.	1.9	12
139	P53 mutations and microsatellite analysis of loss of heterozygosity in malignant gliomas. Cancer Genetics and Cytogenetics, 1994, 74, 139-143.	1.0	11
140	Tumor-initiating cell frequency is relevant for glioblastoma aggressiveness. Oncotarget, 2016, 7, 71491-71503.	1.8	11
141	Meningo-cortical calcifying angiomatosis and celiac disease. Clinical Neurology and Neurosurgery, 1998, 100, 209-215.	1.4	10
142	Molecular markers of gliomas: a clinical approach. Neurological Research, 2006, 28, 538-541.	1.3	10
143	Mutations targeting the coagulation pathway are enriched in brain metastases. Scientific Reports, 2017, 7, 6573.	3.3	10
144	Long and Very-Long-Chain Ceramides Correlate with A More Aggressive Behavior in Skull Base Chordoma Patients. International Journal of Molecular Sciences, 2019, 20, 4480.	4.1	10

#	ARTICLE	IF	CITATIONS
145	Confocal Laser Microscopy in Neurosurgery: State of the Art of Actual Clinical Applications. Journal of Clinical Medicine, 2021, 10, 2035.	2.4	10
146	Intracranial dissemination of pituitary adenoma. Case report and review of the literature. Italian Journal of Neurological Sciences, 1994, 15, 195-200.	0.1	9
147	Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. Journal of Neuro-Oncology, 2000, 49, 71-75.	2.9	9
148	Modulation of Experimental Allergic Encephalomyelitis in Lewis Rats by Administration of a Peptide of Fas Ligand. Journal of Autoimmunity, 2001, 17, 273-280.	6.5	9
149	Production and post-surgical modification of VEGF, tPA and PAI-1 in patients with glioma. Cancer Biology and Therapy, 2006, 5, 204-209.	3.4	9
150	Intracerebral haemorrhage in primary and metastatic brain tumours. Neurological Sciences, 2008, 29, 264-265.	1.9	9
151	Cytochromec oxidase and coenzyme Q in neuromuscular diseases: a histochemical study. Acta Neuropathologica, 1990, 81, 25-29.	7.7	8
152	Preoperative Embolization of Carotid Chemodectoma: A Technical Challenge that can be Customized According to Angioarchitecture. Neuroradiology Journal, 2013, 26, 678-682.	1.2	8
153	5-ALA Fluorescence in Case of Brain Abscess by Aggregatibacter Mimicking Glioblastoma. World Neurosurgery, 2019, 125, 175-178.	1.3	8
154	Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches. Cancers, 2021, 13, 6156.	3.7	8
155	Expression of vascular endothelial growth factor receptor-1/-2 and nitric oxide in unruptured intracranial aneurysms. Neurological Sciences, 2010, 31, 617-623.	1.9	7
156	Peri-operative prognostic factors for primary skull base chordomas: results from a single-center cohort.. Acta Neurochirurgica, 2021, 163, 689-697.	1.7	7
157	IL-4 Gene Transfer for the Treatment of Experimental Gliomas. Advances in Experimental Medicine and Biology, 1998, 451, 315-321.	1.6	7
158	Neuromyelitis Optica in a Child with Atypical Onset and Severe Outcome. Neuropediatrics, 2004, 35, 198-201.	0.6	4
159	Spinal cord stimulation for recurrent painful neuromas of the foot. Neurological Sciences, 2011, 32, 723-725.	1.9	4
160	Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis. Quantitative Imaging in Medicine and Surgery, 2017, 7, 592-597.	2.0	4
161	mTORC1 promotes malignant large cell/anaplastic histology and is a targetable vulnerability in SHH-TP53 mutant medulloblastoma. JCI Insight, 2021, 6, .	5.0	3
162	Sporadic Distal Myopathy with Early Adult Onset: Study of Muscle Biopsies and Muscle Cell Cultures. European Neurology, 1989, 29, 287-290.	1.4	2

#	Article	IF	Citations
163	Low frequency of NF1 gene mutations in malignant gliomas. European Journal of Cancer, 1993, 29, 1217-1218.	2.8	2
164	Letter to the Editor. Neuritis ossificans. Journal of Neurosurgery, 2014, 121, 1287-1289.	1.6	2
165	A case of medulloblastoma in adult patient affected by anaplastic oligoastrocytoma. Neurological Sciences, 2016, 37, 1727-1730.	1.9	2
166	Neuro-Behçet's disease presenting as an isolated progressive cognitive and behavioral syndrome. Neurocase, 2018, 24, 238-241.	0.6	2
167	Radio-Guided Surgery with Î²â˜ Radiation: Tests on Ex-Vivo Specimens. IFMBE Proceedings, 2019, , 693-697.	0.3	2
168	Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series. Neurological Sciences, 2020, 41, 2111-2120.	1.9	2
169	Gene Transfer of Suicide Genes for the Treatment of Malignant Gliomas: Efficacy, Limitations, and Perspectives for a Combined Immunotherapy. , 1997, 68, 100-104.		2
170	OMICS AND PROGNSTIC MARKERS. Neuro-Oncology, 2013, 15, iii136-iii155.	1.2	1
171	Involvement of the CXCL12/CXCR4/CXCR7 Axis in Brain Metastases. , 2014, , 25-36.		1
172	ME-16 * IS AQUAPORIN4 (AQP4) INVOLVED IN ADULT HUMAN MEDULLOBLASTOMA DISSEMINATION OR IN A BENEFICIAL BARRIER FORMATION?. Neuro-Oncology, 2014, 16, v123-v123.	1.2	1
173	Unique combination of myxopapillary ependymoma and conus lipoma with subcutaneous extension in an 11-month-old child. Child's Nervous System, 2018, 34, 597-599.	1.1	1
174	PATH-31. GIANT CELL GLIOBLASTOMAS: ANALYSIS OF MISMATCH-REPAIR (MMR) PROTEINS EXPRESSION, POLIMERASE Îµ (POLE) MUTATIONS AND THEIR ROLE IN TUMOR IMMUNORESPONSE. Neuro-Oncology, 2018, 20, vi165-vi165.	1.2	1
175	Sleeve-Shaped Neurothekeoma of the Ulnar Nerve: A Unique Case of a Still Unclear Pathological Entity. Hand, 2020, 15, NP7-NP10.	1.2	1
176	CTIM-24. AUTOLOGOUS CD34+ ENRICHED HEMATOPOIETIC PROGENITOR CELLS GENETICALLY MODIFIED FOR HUMAN INTERFERON-Î±2, ARE WELL TOLERATED & RAPIDLY ENGRAFT IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (TEM-GBM_001 STUDY). Neuro-Oncology, 2020, 22, ii38-ii38.	1.2	1
177	Abstract A031: CD8+T cells fail to form an effector memory in glioblastoma patients treated with dendritic cell immunotherapy in combination with chemotherapy. Cancer Immunology Research, 2016, 4, A031-A031.	3.4	1
178	Medulloblastoma histological variants as the most powerful prognostic indicator: A 10-year mono-institutional experience.. Journal of Clinical Oncology, 2010, 28, 9556-9556.	1.6	1
179	Results of nimotuzumab and vinorelbine, radiation, and re-irradiation for diffuse pontine glioma in childhood.. Journal of Clinical Oncology, 2014, 32, 10020-10020.	1.6	1
180	CEREBRAL PREAMYLOID DEPOSITS AND CONGOPHILIC ANGIOPATHY IN AGED DOGS. Journal of Neuropathology and Experimental Neurology, 1990, 49, 331.	1.7	0

#	Article	IF	Citations
181	Synaptic alterations in preamyloid deposits. Neurobiology of Aging, 1990, 11, 310.	3.1	0
182	Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. European Journal of Nuclear Medicine and Molecular Imaging, 1994, 21, 314.	2.1	0
183	TOPOGRAPHY OF PHOSPHORYLATED TAU IMMUNOREACTIVITY IN ALZHEIMER DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY AND PICK DISEASE. Journal of Neuropathology and Experimental Neurology, 1996, 55, 634.	1.7	0
184	Utilizzo intraoperatorio delle immagini di spettroscopia RM nella chirurgia dei tumori cerebrali e correlazione con la neuropatologia. The Neuroradiology Journal, 2001, 14, 9-12.	0.1	0
185	109 Tyrosine Kinase Receptors as Functional Markers and Therapeutical Targets of Glioblastoma Stem Cells. European Journal of Cancer, 2012, 48, S27.	2.8	0
186	P12. Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses. , 2014, 2, .		0
187	MPTH-28STUDY OF THE ROLE OF IFI-16 EXPRESSION IN GLIOMAS. Neuro-Oncology, 2015, 17, v144.3-v144.	1.2	0
188	IMCT-06SURVIVAL GAIN AND IMMUNE RESPONSE IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL IMMUNOTHERAPY BEFORE AND DURING ADJUVANT TEMOZOLOMIDE. Neuro-Oncology, 2015, 17, v108.2-v108.	1.2	0
189	HG-56HISTONE K27M MUTATION IN A SERIES OF CENTRALLY REVIEWED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): CONSISTENCY WITH MRI FEATURES. Neuro-Oncology, 2016, 18, iii60.3-iii60.	1.2	0
190	HG-11BRAF V600E MUTATION IN PEDIATRIC ASTROBLASTOMAS. Neuro-Oncology, 2016, 18, iii50.1-iii50.	1.2	0
191	MPTH-42. NEUROPATHOLOGICAL AND MOLECULAR CHARACTERIZATION OF LONG-TERM SURVIVAL GLIOBLASTOMAS (LS-GBM): AÂSTUDY ON 52 CASES. Neuro-Oncology, 2016, 18, vi115-vi115.	1.2	0
192	P03.13 Molecular and clinical bio-markers in a series of 48 consecutive skull base chordoma patients. Neuro-Oncology, 2017, 19, iii36-iii36.	1.2	0
193	P16.14 Treatment of thalamic glial lesions: surgery versus biopsy. Neuro-Oncology, 2017, 19, iii112-iii112.	1.2	0
194	[OA109] Validation of a radio-guided surgery technique based on beta-radiation: Test on ex-vivo specimens. Physica Medica, 2018, 52, 42.	0.7	0
195	P05.02 A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+ enriched hematopoietic progenitor cells genetically modified for human interferon-Î±2 in patients with GBM and an unmethylated MGMT promoter (TEM-GBM-001). Neuro-Oncology, 2019, 21, iii34-iii34.	1.2	0
196	P09.03 Array-CGH analysis in meningiomas adds further information of biological behavior. Neuro-Oncology, 2019, 21, iii39-iii39.	1.2	0
197	MNGI-07. TRIMETHYLATED H3K27 AND EZH2 EXPRESSION IN MENINGIOMA: CORRELATION WITH TENDENCY TO RECUR. Neuro-Oncology, 2019, 21, vi140-vi140.	1.2	0
198	ATIM-36. TEM-GBM-001 STUDY: AUTOLOGOUS CD34+ ENRICHED HEMATOPOIETIC PROGENITOR CELLS GENETICALLY MODIFIED FOR HUMAN INTERFERON-Î±2 & ADMINISTERED TO PATIENTS WITH GLIOBLASTOMA & AN UNMETHYLATED MGMT PROMOTER. Neuro-Oncology, 2019, 21, vi9-vi9.	1.2	0

#	Article	IF	Citations
199	P14.64 Primary Central Nervous System Lymphoma (PCNSL) with HD- MTX based chemotherapy: tolerability and results. Neuro-Oncology, 2019, 21, iii82-iii82.	1.2	0
200	P14.74 Remarkable response to Combined BRAF and MEK Inhibitors in two Adults with leptomeningeal carcinomatosis secondary to Pleomorphic Xantoastrocytoma grade II with BRAFv600E mutation. Neuro-Oncology, 2019, 21, iii85-iii85.	1.2	0
201	Association of increased survival in glioblastoma patients treated with dendritic cell vaccinations and temozolomide with increased activity of NK cells and ABCC3 expression.. Journal of Clinical Oncology, 2016, 34, 2039-2039.	1.6	0
202	Tetanus toxoid pre-conditioning in recurrent glioblastoma treated with dendritic cell immunotherapy is associated to CD8+ T cell response.. Journal of Clinical Oncology, 2018, 36, e14053-e14053.	1.6	0
203	EPEN-03. LONG-TERM FOLLOW-UP OF AIEOP 2ND SERIES OF CHILDREN AND ADOLESCENT WITH PRIMARY INTRACRANIAL (ST:SUPRATENTORIAL; PF: POSTERIOR FOSSA) EPENDYMOMA AND METHYLATION GROUPS RE-ANALYSES. Neuro-Oncology, 2020, 22, iii308-iii308.	1.2	0
204	How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment. Journal of Neuro-Oncology, 0, , .	2.9	0